| A phase 2, randomized dose-finding study of tapinarof (GSK2894512 cream) for the treatment of atopic dermatitis J Peppers, AS Paller, T Maeda-Chubachi, S Wu, K Robbins, K Gallagher, ... Journal of the American Academy of Dermatology 80 (1), 89-98. e3, 2019 | 146 | 2019 |
| Prevalence and incidence rates of cardiovascular, autoimmune, and other diseases in patients with psoriatic or psoriatic arthritis: a retrospective study using Clinical … E Edson‐Heredia, B Zhu, C Lefevre, M Wang, A Barrett, CJ Bushe, A Cox, ... Journal of the European Academy of Dermatology and Venereology 29 (5), 955-963, 2015 | 114 | 2015 |
| Phase 2, randomized dose-finding study of tapinarof (GSK2894512 cream) for the treatment of plaque psoriasis K Robbins, R Bissonnette, T Maeda-Chubachi, L Ye, J Peppers, ... Journal of the American Academy of Dermatology 80 (3), 714-721, 2019 | 96 | 2019 |
| Heterogeneity of response to biologic treatment: perspective for psoriasis E Edson-Heredia, KL Sterling, CI Alatorre, GC Carter, R Paczkowski, ... Journal of Investigative Dermatology 134 (1), 18-23, 2014 | 93 | 2014 |
| Itching is a significant problem and a mediator between disease severity and quality of life for patients with psoriasis: results from a randomized controlled trial B Zhu, E Edson‐Heredia, J Guo, T Maeda‐Chubachi, W Shen, AB Kimball British Journal of Dermatology 171 (5), 1215-1219, 2014 | 62 | 2014 |
| Comparison of latanoprost and timolol in pediatric glaucoma: a phase 3, 12-week, randomized, double-masked multicenter study T Maeda-Chubachi, K Chi-Burris, BD Simons, SF Freedman, PT Khaw, ... Ophthalmology 118 (10), 2014-2021, 2011 | 54 | 2011 |
| Disease burden and quality of life in psoriasis patients with and without comorbid psoriatic arthritis: results from National Psoriasis Foundation panel surveys E Edson-Heredia, B Zhu, J Guo, T Maeda-Chubachi, M Lebwohl Cutis 95 (3), 173-8, 2015 | 39 | 2015 |
| Systemic pharmacokinetics, safety, and preliminary efficacy of topical AhR agonist Tapinarof: Results of a phase 1 study R Bissonnette, LS Vasist, JN Bullman, T Collingwood, G Chen, ... Clinical Pharmacology in Drug Development 7 (5), 524-531, 2018 | 36 | 2018 |
| Understanding the Relationship Between Pruritus Severity and Work Productivity in Patients With Moderate-to-Severe Psoriasis: Sleep Problems Are a Mediating Factor. AB Kimball, E Edson-Heredia, B Zhu, J Guo, T Maeda-Chubachi, W Shen, ... Journal of drugs in dermatology: JDD 15 (2), 183-188, 2016 | 36 | 2016 |
| Latanoprost systemic exposure in pediatric and adult patients with glaucoma: a phase 1, open-label study S Raber, R Courtney, T Maeda-Chubachi, BD Simons, SF Freedman, ... Ophthalmology 118 (10), 2022-2027, 2011 | 36 | 2011 |
| A high level of clinical response is associated with improved patient-reported outcomes in psoriasis: analyses from a phase 2 study in patients treated with ixekizumab. E Edson‐Heredia, S Banerjee, B Zhu, T Maeda‐Chubachi, GS Cameron, ... Journal of the European Academy of Dermatology & Venereology 30 (5), 2016 | 33 | 2016 |
| Efficacy and safety of topical nitric oxide− releasing berdazimer gel in patients with molluscum contagiosum: A phase 3 randomized clinical trial JC Browning, C Enloe, M Cartwright, A Hebert, AS Paller, D Hebert, ... JAMA dermatology 158 (8), 871-878, 2022 | 30 | 2022 |
| Efficacy and tolerability of an investigational nitric oxide–releasing topical gel in patients with molluscum contagiosum: A randomized clinical trial AA Hebert, EC Siegfried, T Durham, EN de León, T Reams, ... Journal of the American Academy of Dermatology 82 (4), 887-894, 2020 | 30 | 2020 |
| A phase 2 controlled study of SB206, a topical nitric oxide-releasing drug for extragenital wart treatment. SK Tyring, T Rosen, B Berman, N Stasko, T Durham, T Maeda-Chubachi Journal of Drugs in Dermatology: JDD 17 (10), 1100-1105, 2018 | 18 | 2018 |
| Measuring atopic eczema control and itch intensity in clinical practice: a consensus statement from the Harmonising Outcome Measures for Eczema in Clinical Practice (HOME-CP … YA Leshem, JR Chalmers, C Apfelbacher, N Katoh, LAA Gerbens, ... JAMA dermatology 158 (12), 1429-1435, 2022 | 15 | 2022 |
| Impact of age, diagnosis, and history of glaucoma surgery on outcomes in pediatric patients treated with latanoprost T Maeda-Chubachi, K Chi-Burris, B Simons, D Brémond-Gignac, ... Journal of Glaucoma 22 (8), 614-619, 2013 | 14 | 2013 |
| SB206, a nitric oxide–releasing topical medication, induces the beginning of the end sign and molluscum clearance T Maeda-Chubachi, D Hebert, E Messersmith, EC Siegfried JID Innovations 1 (3), 100019, 2021 | 12 | 2021 |
| A nitric oxide-releasing topical medication as a potential treatment option for atopic dermatitis through antimicrobial and anti-inflammatory activity E Guttman-Yassky, RL Gallo, AB Pavel, T Nakatsuji, R Li, N Zhang, ... The Journal of investigative dermatology 140 (12), 2531-2535. e2, 2020 | 9 | 2020 |
| Berdazimer gel for molluscum contagiosum: An integrated analysis of 3 randomized controlled trials JL Sugarman, A Hebert, JC Browning, AS Paller, S Stripling, LJ Green, ... Journal of the American Academy of Dermatology 90 (2), 299-308, 2024 | 6 | 2024 |
| Efficacy and safety of berdazimer 10.3%, a nitric oxide-releasing topical gel in patients with molluscum contagiosum: a phase 3 randomized clinical trial J Browning, C Enloe, MHA Cartwright, A Paller, D Hebert, E Kowalewski, ... JAMA Derm, 2022 | 6 | 2022 |
